Vitaxin

Vitaxin is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. At this time Vitaxin was in 2002 being studied for rheumatoid arthritis.[2]

References

  1. ↑ F. Vande Woude, George; George Klein (2000). Advances in Cancer Research. Academic Press. p. 27. ISBN 978-0-12-006679-7.
  2. ↑ Wilder, RL. "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.". Ann Rheum Dis. 61 Suppl 2: ii96–9. PMC 1766704 Freely accessible. PMID 12379637.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.